M.B.A

NewAmsterdam Pharma Announces Appointment of William “BJ” Jones, formerly of Biohaven Pharmaceuticals, as Chief Commercial Officer

Retrieved on: 
Montag, August 14, 2023
Industrial engineering, Dyslipidemia, Marketing, Texas A&M University, Cardiovascular disease, Business, NAMS, Apolipoprotein, Bristol Myers Squibb, CCO, AstraZeneca, Boehringer Ingelheim, Migraine, Patient, CETP, M.B.A, Stanford Graduate School of Business, Pfizer, Takeda Pharmaceutical Company, Common, Pharmaceutical industry, Nitrome

Mr. Jones brings 30 years of commercial and launch experience in the U.S. and globally, with particular experience in driving mass market product launch strategies for industry-leading brands.

Key Points: 
  • Mr. Jones brings 30 years of commercial and launch experience in the U.S. and globally, with particular experience in driving mass market product launch strategies for industry-leading brands.
  • At NewAmsterdam, he will build and lead all commercial functions, including marketing, market access, sales, medical science engagement and commercial operations.
  • Most recently, he served as CCO, Migraine & Common Diseases at Biohaven Pharmaceuticals, which was acquired by Pfizer for $11.6B.
  • During his tenure, Mr. Jones led the commercial enterprise that launched Biohaven’s Nurtec® ODT.

Rockefeller Global Family Office Welcomes Angela Mwanza, Jordan Powell and Team, Further Expanding Firm’s New York Presence

Retrieved on: 
Freitag, August 11, 2023
Finance, Consulting, Banking, Professional Services, Asset Management, Mwanza, Powell, University, CFA, High-net-worth individual, Wealth, Private, CIBC Wood Gundy, University of Konstanz, National Field of Honour, Consultant, Business, Chartered, Derivative, Associate, Linguistics, J.P. Morgan & Co., BNP Paribas, Cornell University, Investment, Risk, Wang Wenyi, M.B.A, New York University Stern School of Business, M.A, Commodity, Samuel Curtis Johnson Graduate School of Management, Family, Rockefeller Capital Management, Financial services, Management, FTSE Global Equity Index Series, Indiana University, Jumia

Rockefeller Global Family Office (“Rockefeller”), the wealth management division of Rockefeller Capital Management, today announced that Angela Mwanza and Jordan Powell, two of the industry’s preeminent private wealth advisors, and their four-person team, Oryx Legacy Partners, have joined the firm.

Key Points: 
  • Rockefeller Global Family Office (“Rockefeller”), the wealth management division of Rockefeller Capital Management, today announced that Angela Mwanza and Jordan Powell, two of the industry’s preeminent private wealth advisors, and their four-person team, Oryx Legacy Partners, have joined the firm.
  • She joins Rockefeller from UBS Private Wealth Management where she spent 15 years as a Private Wealth Advisor and one of a select few Family Office Consultants.
  • Prior to Rockefeller, he joined UBS Private Wealth Management from BNP Paribas where he was a Vice President in Global Equities, Commodities and Derivatives.
  • “Angela and her team are widely recognized as being among the industry’s leading purpose-driven wealth management professionals, and we are pleased to welcome them to Rockefeller,” said Christopher Dupuy, Co-President of Rockefeller Global Family Office.

Intellectual Property Attorney Ivan Gracic joins McDonald Hopkins

Retrieved on: 
Montag, Juli 31, 2023
Ohio State University, Weatherhead School of Management, University, Face, Case Western Reserve University, IP, Associate, Patent, M.B.A, Engineering, Law, R, Software

CLEVELAND, July 31, 2023 /PRNewswire/ -- Ivan Gracic has joined McDonald Hopkins LLC as an Associate, adding his patent expertise to the firm's Intellectual Property Department.

Key Points: 
  • CLEVELAND, July 31, 2023 /PRNewswire/ -- Ivan Gracic has joined McDonald Hopkins LLC as an Associate, adding his patent expertise to the firm's Intellectual Property Department.
  • In addition to his patent expertise, Gracic brings forth experience in trademark and copyright law, and IP litigation.
  • Founded in 1930, McDonald Hopkins is a business advisory and advocacy law firm with locations in Baltimore/Annapolis, Chicago, Cleveland, Columbus, Detroit, and West Palm Beach.
  • For more information about McDonald Hopkins, visit mcdonaldhopkins.com .

Invivyd Announces Appointment of Sara Cotter to Board Of Directors

Retrieved on: 
Donnerstag, Juli 27, 2023
EUA, Prader–Willi syndrome, Portfolio manager, SVKM's NMIMS, Drug development, University, AbbVie, Abbott Laboratories, COVID-19, Kellogg School, Antibody, Northfield Laboratories, M.B.A, UBS, Immunodeficiency, Notre Dame, Northwestern University, Pharmaceutical industry

WALTHAM, Mass., July 27, 2023 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases, today announced the appointment of Sara Cotter to its board of directors.

Key Points: 
  • WALTHAM, Mass., July 27, 2023 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases, today announced the appointment of Sara Cotter to its board of directors.
  • Ms. Cotter brings extensive leadership experience spanning healthcare investment management and drug development.
  • Cotter’s comprehensive knowledge of the biopharmaceutical industry, pairing both operating and capital markets expertise, make her an excellent addition to our board of directors,” said Dave Hering, Chief Executive Officer of Invivyd.
  • Ms. Cotter received an M.B.A from the Kellogg School of Management at Northwestern University and a B.S.

A-Alpha Bio Welcomes Heidi Hagen to Its Board of Directors

Retrieved on: 
Dienstag, Juni 27, 2023
Obsidian, Molecular biology, Operation, Senior, Biotechnology, Dendreon, University, Therapy, Immune tolerance, College of Engineering (KNUST), Former, Science, Charles Henry Chapman (Alpha Phi Alpha co-founder), Machine learning, M.B.A, University of Washington Department of Bioengineering, Alpha-enolase, Engineering, Medicine, Sotio, Ideation, Growth, Entrepreneurship, Health, Corporate title, Synthetic biology, Management, Regulatory T cell

SEATTLE, June 27, 2023 /PRNewswire-PRWeb/ -- A-Alpha Bio, a synthetic biology and machine learning company that measures and engineers protein-protein interactions, announced the appointment of Heidi Hagen to their Board of Directors. Hagen will be A-Alpha Bio's first independent board member.

Key Points: 
  • Hagen, Former Chief Technical Officer of Sonoma Biotherapeutics, Joins as A-Alpha's First Independent Board Member
    SEATTLE, June 27, 2023 /PRNewswire-PRWeb/ -- A-Alpha Bio , a synthetic biology and machine learning company that measures and engineers protein-protein interactions, announced the appointment of Heidi Hagen to their Board of Directors.
  • "We are thrilled to welcome Heidi to our Board of Directors," said David Younger, CEO and Co-Founder of A-Alpha Bio.
  • Based in Seattle, Hagen will be on the ground to support and share her expertise and network with the A-Alpha Bio team.
  • "I am excited to join A-Alpha Bio's Board of Directors and collaborate with this dynamic team of biologists, protein engineers, and data scientists," said Hagen.

iBio Appoints Dr. Martin Brenner as CEO, Felipe Duran as CFO to Oversee Company’s Next Stage of Growth

Retrieved on: 
Dienstag, Juni 27, 2023
Vaccine, Teva Pharmaceuticals, Ludwig Maximilian University of Munich, Good, Executive, University, FP, CSO, Biotechnology, Education minister, Pfizer, Finance, RNA, AstraZeneca, Quality, Merck & Co., Lupinus, Protein, Lupin Limited, Machine learning, SAN, M.B.A, Drug discovery, CFO, Growth, Eli Lilly and Company, Artificial intelligence, Therapy, DVM, Automation, Management, Pharmaceutical industry, Science, Pharmacology

BRYAN, Texas and SAN DIEGO, June 27, 2023 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, today announced the appointments of Martin Brenner, DVM, Ph.D. as Chief Executive Officer; and Felipe Duran as Chief Financial Officer, effective immediately. Dr. Brenner will also continue to serve as iBio's Chief Scientific Officer, a role he has held since December 2020.

Key Points: 
  • Dr. Brenner will also continue to serve as iBio's Chief Scientific Officer, a role he has held since December 2020.
  • The permanent appointments reflect the Board of Directors’ confidence in Dr. Brenner and Mr. Duran, who have respectively served as iBio’s interim CEO and CFO since early 2023, to complete the strong management team required to lead the Company in its next stage of growth.
  • Martin and Felipe are the right people to lead iBio.
  • During his tenure at Lupin, Mr. Duran functioned as a key member for the Latin American executive team, supporting both Mexico and Brazil.

The Knot Worldwide Welcomes Marketing and Consumer Technology Leader Carolyn Everson to its Board of Directors

Retrieved on: 
Montag, Juni 26, 2023
Bridal, Retail, The Coca-Cola Company, Advertising, Viacom, Columbia University Vagelos College of Physicians and Surgeons, Gen, Meta, Permira, Policy, Jefferson Literary and Debating Society, Everson, Microsoft, The Knot Worldwide, Council, Generation Z, Villanova University, Name, M.B.A, Foreign policy, Harvard Business School, Senior advisor, Humane society, Knot, Family, The Walt Disney Company, Management, Instacart

The Knot Worldwide , a leading global marketplace and family of brands championing celebration, announced today that Carolyn Everson has joined the organization’s board of directors , effective March 22, 2023.

Key Points: 
  • The Knot Worldwide , a leading global marketplace and family of brands championing celebration, announced today that Carolyn Everson has joined the organization’s board of directors , effective March 22, 2023.
  • Everson brings over 28 years of experience to The Knot Worldwide’s board, including having held executive and advisory roles at global consumer businesses.
  • Most recently, Everson served as President of Instacart, where she oversaw the fast-growing company’s advertising, partnerships, policy and legal teams.
  • “I’m incredibly excited to be a part of The Knot Worldwide’s board during a time when the wedding industry is reaching an inflection point,” said Carolyn Everson.

Catalent Appoints Matti Masanovich Senior Vice President & Chief Financial Officer

Retrieved on: 
Dienstag, Juni 20, 2023
Biotechnology, Pharmaceutical, Health, General Cable, LLP, University, Senior, CTLT, Tenneco, History, PwC, Apollo, CDMO, Patient, Collection, M.B.A, NYSE, Commerce, Management, Catalent

Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced that Matti Masanovich has been named Senior Vice President & Chief Financial Officer, effective July 5, 2023.

Key Points: 
  • Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced that Matti Masanovich has been named Senior Vice President & Chief Financial Officer, effective July 5, 2023.
  • Prior to joining Catalent, Mr. Masanovich served as Executive Vice President & Chief Financial Officer of Tenneco Automotive until it was acquired by Apollo.
  • Previously he was Chief Financial Officer at Superior Industries International and General Cable Corporation.
  • “Matti is a proven finance leader whose deep experience growing and driving profitability at publicly traded, complex global manufacturing companies is ideally suited to help Catalent reach its next level of performance, including enhanced profitability and value-creation for shareholders,” said Alessandro Maselli, President and Chief Executive Officer of Catalent.

Femasys Inc. Replaces Two Board Members with Seasoned Industry Leaders in the Life Sciences

Retrieved on: 
Donnerstag, Juni 15, 2023
Human resources, IPO, Commodity Credit Corporation, AT, Biotechnology, Communication, Woman, Audit committee, Gazprom, Pace University, M.B.A, CFO, Growth, Reckitt, Health, Therapy, Rio Tinto, Management

ATLANTA, June 15, 2023 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women’s needs worldwide by developing a suite of product candidates that include minimally invasive, in-office technologies for reproductive health, today announced that it has appointed Mr. Keith J. Kendall and Mr. Alistair Milnes to its board of directors. Messrs. Kendall and Milnes will be replacing Mr. John Dyett, who currently serves as Co-CEO of Salem Partners, LLC and Salem Partners Wealth Management, LLC and Mr. John Adams, formerly served as CEO and President of Adams Respiratory Therapeutics, who both have served as members of Femasys’ board of directors for over eight years. Mr. Kendall will also replace Mr. Dyett as Audit Committee Chair.

Key Points: 
  • Mr. Kendall will also replace Mr. Dyett as Audit Committee Chair.
  • Ms. Kathy Lee-Sepsick, founder, president and chief executive officer of Femasys, commented, “We are excited to welcome Keith Kendall and Alistair Milnes to our board.
  • Mr. Milnes’ experience as a biotechnology executive includes leadership experience in expediting company growth and market expansion.
  • Mr. Milnes, commented, “I am thrilled to join Femasys’ board of directors at this exciting time of growth for the Company.

DAMONA Pharmaceuticals Appoints John Reilly as Chief Executive Officer

Retrieved on: 
Dienstag, Juni 13, 2023
Depression, Doctor of Philosophy, ABCL, Hepatology, Biotechnology, Ageing, Business, Hamilton College, DSM-IV codes, APIC, SOD1, Entrepreneurship, M.B.A, Therapy, Cornell University, IND, ALS, Pharmaceutical industry, AbCellera

TORONTO, June 13, 2023 /PRNewswire/ -- DAMONA Pharmaceuticals, a preclinical biopharmaceutical company focused on the discovery and development of first-in-class small molecules for the treatment and prevention of cognitive symptoms associated with brain disorders and aging, today announced the appointment of John Reilly as the company's Chief Executive Officer and member of the Board of Directors.

Key Points: 
  • TORONTO, June 13, 2023 /PRNewswire/ -- DAMONA Pharmaceuticals, a preclinical biopharmaceutical company focused on the discovery and development of first-in-class small molecules for the treatment and prevention of cognitive symptoms associated with brain disorders and aging, today announced the appointment of John Reilly as the company's Chief Executive Officer and member of the Board of Directors.
  • "We feel very fortunate to have attracted John into the role of CEO for Damona.
  • "I'm ecstatic to have John join the DAMONA team as CEO.
  • John brings a great background to DAMONA with a proven track record of building and managing high-performance preclinical and clinical biopharmaceutical teams that deliver results," said Jacki Jenuth, Partner and Chief Operating Officer of Lumira Ventures.